The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The clinical trial mentioned in the following passage about a typical day in the life of Dr William Tap at MSK Cancer Centre was ours!!
“11:15 AM: Jason Chan, one of Dr. Tap’s two medical oncology fellows, pokes his head in the doorway. (Dr. Tap has a general open-door policy.) He’s just met with a patient and wants to give Dr. Tap the rundown. The person is considering leaving her primary oncologist, near her home, and coming to MSK.
The woman has been diagnosed with gastrointestinal stromal tumor (GIST), a rare cancer that develops in the digestive tract. Dr. Tap’s visit with the family lasts nearly 30 minutes. He explains that MSK’s extensive expertise offers the best hope for a positive outcome, but also suggests he can coordinate care with her local oncologist. “What she really needs is to be treated here on a clinical trial,” he says after he leaves her consultation room. But all he can offer today is guidance.”
Outsmarting Sarcoma: How MSK’s Experts Are Advancing Treatment and Research Progress | Memorial Sloan Kettering Cancer Center
I love the reference to pre|CISION-ADC (Aff Drug Conjugate) which have appeared in the Avacta website over the last couple of days and the fact that they are using affimers which have many advantages over the antibodies used in the conventional ADCs which as we know are selling for $billions. It really does look as if they are gearing themselves up!
A quote from the web site
“ The mechanism of action of the pre|CISION-ADC model optimises warhead delivery by targeting the warhead to the TME in two ways: with the antibody or Affimer® target and FAP-release in the TME.“
Exciting times! GLA
I’m hoping it’ll stay at around the £1.20 mark as I’m wanting to bed and ISA at the start of the next tax year. This will mean selling as many shares as I can from my trading account around 30 March to allow time for the settlement date to be on or before 5 April. I then intend buying back in my ISA on 6 April, hoping and 🤞that the share price remains at around the level I sold them at. The problem is that the AACR is due to take place in San Diego between 5-10 April. If Avacta are present and divulge more exciting data I’m going to be snookered!! Any suggestions?
I’m also stage 1 prostate cancer and under observation. My local hospital monitor me with 6 monthly tests but having had 2 MRI scans, the last being nearly 2 years ago, are reticent to give me a further MRI scan unless the PSA reading goes up significantly. I was told when I was first diagnosed in 2020 that I’d have a 6 monthly PSA test and an MRI scan every 12 months. This change of policy must be to save costs for the NHS.
It would be great if affimers could be utilised in providing a diagnostic test and as cj62 suggests AVA6k used in small doses to try and kill the tumour before it gets bigger.
Thanks for the replies
I’m not so sure if the advice about ISA held AIM stocks not qualifying is correct.
According to ii their advice is
“ Passing on more wealth
Certain AIM shares qualify for Business Property Relief. This means that after being held for two years, the value of any qualifying AIM shares in your ISA will be excluded from your inheritance tax calculation. You must have held these shares for at least two years and still be holding them on your death for them to qualify for exemption.
Investing in AIM shares via an ISA means that you benefit from tax breaks and your inheritors can receive 100% of the value.”
Am I correct in believing that the value of shares in Avacta are exempt from Inheritance Tax if they’ve been held for more than two years as it’s an AIM listed Company.
For those of us of a certain age and with potential huge gains in the value of our holdings, this is an enormous advantage.
If we were to be listed on NASDAQ presumable this advantage would be lost!
On 22 December last year we received the RNS (AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing) we had all been patiently waiting for. Let’s hope we receive GREAT news just before Christmas this year! (smiley emoji)
This is absurd. Best lateral flow test in the world being blocked by HMG’s red tape whilst the EU has now allowed them to be used at home all across Europe. At the same time pharmacies in UK running out of the cheap poorer quality Chinese tests. It is just beginning to sink in with the wider population in this country that something is amiss although the vast majority still have never heard of Avacta or what it has managed to achieve. Has anyone on this bulletin board every tried writing “Letters to the Editor” of the major newspapers to try and get greater coverage of this scandalous state of affairs? Just wondering if it’s worth doing or whether editors will simply block such correspondence?
Following the presentation on 30 September this year, it was indicated by Investor Meet Company that they would issue replies by Avacta to some of the many questions put forward by investors. Has anyone seen these replies and if so, can you please share a link.
In the guidance for the Desk Top Review, (https://www.gov.uk/guidance/lateral-flow-validation-prioritisation-criteria-for-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens), item 4 in the Primary Selection Criteria states:
“4. The lateral flow device must be specific for nucleocapsid antigens.” This on the face of it would rule out our test which is aimed to target the spike.
However, the last paragraph of the guidance comes to our rescue when it states
“DHSC recognises that it is not possible to predict every possible innovation. If a manufacturer has developed a test with an unforeseen advantage, we reserve the right to review and permit submission for validation if the scientific consensus supports the claim.”